CAS:100

Indication:OPDIVO® (nivolumab) is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Specification:to be administered by hospital or qualified physician only

Dosage Form:Injection

Active Ingredients:NIVOLUMAB

Route of Administration:Intravenous Drip

Shelf Life:18 months

Storage:2℃-8℃

Package:1 VIAL per pack

Place of Origin:EU

Qualification:EU GMP

Indication:Symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Dosage Form:Tablet

Active Ingredients:Vandetanib 100mg, 300mg, tabs.

Route of Administration:Oral

Shelf Life:18 months

Storage:Below 30℃

Package:30 TAB PER BOTTLE

Place of Origin:EU

Qualification:EU GMP

Indication:Treatment of adults with chronic, accelerated, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinas

Dosage Form:Tablet

Active Ingredients:Pontinib

Route of Administration:Oral

Shelf Life:18 months

Storage:Below 30℃

Package:30 Or 90 Film Coated Tablets

Place of Origin:EU

Qualification:EU GMP

CAS:11041-94-4

Assay:99%

Pharmacopeia:USP

Package Type:foil bag

Shelf Life:2 years

Storage:2℃-8℃

Place of Origin:China

CAS:571189-16-7

Chemical Formula:C14H20N4O4

Molecular Weight:308.33

Assay:99.5%

Pharmacopeia:CP

Shelf Life:18 months

Storage:Sealed

Place of Origin:China

CAS:23795-03-1

Pharmacopeia:CP

Shelf Life:18 months

Storage:Sealed

Pharmacopeia:CP

Shelf Life:18 months

Storage:Sealed

Indication:DCETRIS Indications ADCETRIS® (brentuximab vedotin) is indicated for the treatment of: Previously untreated Stage III/IV classical Hodgkin lymphoma (cHL) Adult patients with previously untreated

Dosage Form:Injection

Active Ingredients:brentuximab vedotin

Route of Administration:Intravenous Drip

Shelf Life:18 months

Storage:2℃-8℃

Package:1 VIAL per pack

Place of Origin:EU

Qualification:EU GMP

Indication:Soliris is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

Dosage Form:Injection

Active Ingredients:Eculizumab

Route of Administration:Intravenous Drip

Shelf Life:18 months

Storage:2℃-8℃

Package:1 vial per carton

Place of Origin:EU

Qualification:EU GMP

CAS:501-36-0

Pharmacopeia:IP

Shelf Life:18 months

Storage:Sealed

CAS:1257044-40-8

Pharmacopeia:USP

Shelf Life:18 months

Storage:Sealed

Dosage Form:Injection

Route of Administration:Oral

Shelf Life:18 months

Storage:Sealed

Qualification:Chinese GMP

Dosage Form:Injection

Route of Administration:Oral

Shelf Life:18 months

Storage:Sealed

Qualification:Chinese GMP